Atrium Health Levine Cancer | Strategic Alliance Partners

April 14, 2022

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.

February 17, 2022

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

January 28, 2022

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

January 07, 2022

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

November 02, 2021

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

October 27, 2021

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

October 05, 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

October 05, 2021

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

September 30, 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

September 27, 2021

Jubilee Brown, MD, contextualizes updates in endometrial cancer and cervical cancer, frontline and second-line maintenance, and novel immune-oncology combination strategies in ovarian cancer.

August 31, 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

July 07, 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.

July 01, 2021

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

June 02, 2021

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

May 20, 2021

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

May 18, 2021

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

May 10, 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

April 30, 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

April 27, 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

April 26, 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.